Patents by Inventor Yosuke Nishigaya

Yosuke Nishigaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952387
    Abstract: [Problem] To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. [Solution] Provided are a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: April 9, 2024
    Assignee: KYORIN PHARMACEUTICAL CO., LTD
    Inventors: Masahiko Kinebuchi, Takekazu Kondou, Koji Ochiai, Yosuke Nishigaya
  • Publication number: 20230127046
    Abstract: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, ?-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).
    Type: Application
    Filed: November 26, 2020
    Publication date: April 27, 2023
    Applicants: RIKEN, TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, MICROBIAL CHEMISTRY RESEARCH FOUNDATION
    Inventors: Tatsunobu SUMIYA, Yosuke NISHIGAYA, Ryosuke NAMIE, Noriaki HASHIMOTO, Akihiro ITO, Fumiyuki SHIRAI, Ko KIKUZATO, Minoru YOSHIDA
  • Publication number: 20220332730
    Abstract: [Problem] To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. [Solution] Provided are a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof.
    Type: Application
    Filed: August 20, 2019
    Publication date: October 20, 2022
    Applicant: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko KINEBUCHI, Takekazu KONDOU, Koji OCHIAI, Yosuke NISHIGAYA
  • Publication number: 20130331378
    Abstract: A pyrazolopyridine derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof exhibits a strong EP1 receptor antagonistic effect. Thus, the derivative or the pharmacologically acceptable salt is useful as a therapeutic agent for lower urinary tract symptoms (LUTS), particularly, overactive bladder syndrome (OABs), or a prophylactic agent therefor and furthermore, is also useful in the treatment, prevention, or suppression of various pathological conditions in which the EP1 receptor is involved, such as inflammatory disease, pain disease, osteoporosis, and cancer. [A is a benzene ring or the like, Y1 is C1-6 alkylene, R1 is —C(?O)—OZ1 or the like, Z1 is H or the like, R2 is a branched C3-6 alkyl group or the like, R3 is H or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like].
    Type: Application
    Filed: January 25, 2012
    Publication date: December 12, 2013
    Applicants: KISSEI PHARMACEUTICAL CO., LTD., KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Shigeki Seto, Kentaro Umei, Yosuke Nishigaya, Asao Tanioka, Tatsuhiro Kondo, Atsushi Kondo, Kazuya Tatani, Naohiro Kawamura